Terms: = Head and neck cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Prognosis
45 results:
1. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers.
Mestiri S; El-Ella DMA; Fernandes Q; Bedhiafi T; Almoghrabi S; Akbar S; Inchakalody V; Assami L; Anwar S; Uddin S; Gul ARZ; Al-Muftah M; Merhi M; Raza A; Dermime S
Biomed Pharmacother; 2024 Feb; 171():116095. PubMed ID: 38183744
[TBL] [Abstract] [Full Text] [Related]
2. Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells.
Grottker F; Gehre S; Reichardt CM; Sengedorj A; Jost T; Rieckmann T; Hecht M; Gostian AO; Frey B; Fietkau R; Gaipl US; Rückert M
Neoplasia; 2023 Nov; 45():100944. PubMed ID: 37857049
[TBL] [Abstract] [Full Text] [Related]
3. Constructing heterogeneous single-cell landscape and identifying microenvironment molecular characteristics of primary and lymphatic metastatic head and neck squamous cell carcinoma.
Zhang J; Liu Y; Xia L; Zhen J; Gao J; Atsushi T
Comput Biol Med; 2023 Oct; 165():107459. PubMed ID: 37713790
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of lymphovascular invasion in patients with pT1b esophageal squamous cell carcinoma.
Liu L; Lin H; Shen G; Liu Y; Qin X; Yuan Y; Wang B; Xue L
BMC Cancer; 2023 Apr; 23(1):370. PubMed ID: 37087442
[TBL] [Abstract] [Full Text] [Related]
5. The Concordant Disruption of B7/CD28 Immune Regulators Predicts the prognosis of Oral Carcinomas.
Chang SR; Chou CH; Liu CJ; Lin YC; Tu HF; Chang KW; Lin SC
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983005
[TBL] [Abstract] [Full Text] [Related]
6. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy.
Wang Y; Du J; Gao Z; Sun H; Mei M; Wang Y; Ren Y; Zhou X
Br J Cancer; 2023 Mar; 128(7):1196-1207. PubMed ID: 36522474
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer.
Jiang S; Li X; Huang L; Xu Z; Lin J
Front Immunol; 2022; 13():988416. PubMed ID: 36119046
[TBL] [Abstract] [Full Text] [Related]
8. Association of immune response with overall and disease-free survival in laryngeal squamous cell carcinomas.
Bayrak AF; Eliyatkın NÖ; İşlek A; Özkul Y; Kılıç HS; Aktas S
Am J Otolaryngol; 2022; 43(4):103477. PubMed ID: 35537231
[TBL] [Abstract] [Full Text] [Related]
9. Genetic variation within the human papillomavirus type 16 genome is associated with oropharyngeal cancer prognosis.
Lang Kuhs KA; Faden DL; Chen L; Smith DK; Pinheiro M; Wood CB; Davis S; Yeager M; Boland JF; Cullen M; Steinberg M; Bass S; Wang X; Liu P; Mehrad M; Tucker T; Lewis JS; Ferris RL; Mirabello L
Ann Oncol; 2022 Jun; 33(6):638-648. PubMed ID: 35306154
[TBL] [Abstract] [Full Text] [Related]
10. PD-L2 based immune signature confers poor prognosis in HNSCC.
Qiao Y; Liu C; Zhang X; Zhou Q; Li Y; Xu Y; Gao Z; Xu Y; Kong L; Yang A; Mei M; Ren Y; Wang X; Zhou X
Oncoimmunology; 2021; 10(1):1947569. PubMed ID: 34377590
[TBL] [Abstract] [Full Text] [Related]
11. Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma.
Inoue S; Yoshida T; Nishino T; Goto M; Aoyama M; Kawakita N; Yamamoto Y; Yoshihito F; Takizawa H; Tangoku A
Gen Thorac Cardiovasc Surg; 2021 Mar; 69(3):525-533. PubMed ID: 33449265
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
Furukawa K; Kawasaki G; Yoshida T; Umeda M
Anticancer Res; 2021 Jan; 41(1):101-111. PubMed ID: 33419803
[TBL] [Abstract] [Full Text] [Related]
13. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
[TBL] [Abstract] [Full Text] [Related]
14. Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment?
Theocharis S; Tasoulas J; Masaoutis C; Kokkali S; Klijanienko J
Expert Opin Ther Targets; 2020 Oct; 24(10):1047-1059. PubMed ID: 32744127
[TBL] [Abstract] [Full Text] [Related]
15.
Ge J; Jiang L; Tian Y; Zheng M; Huang M; Li J
J Int Med Res; 2020 Apr; 48(4):300060520919252. PubMed ID: 32517588
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers.
Okadome K; Baba Y; Nomoto D; Yagi T; Kalikawe R; Harada K; Hiyoshi Y; Nagai Y; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Shono T; Sasaki Y; Baba H
Br J Cancer; 2020 May; 122(10):1535-1543. PubMed ID: 32210369
[TBL] [Abstract] [Full Text] [Related]
17. The Microenvironment of head and neck cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.
Outh-Gauer S; Morini A; Tartour E; Lépine C; Jung AC; Badoual C
Head Neck Pathol; 2020 Jun; 14(2):330-340. PubMed ID: 32124416
[TBL] [Abstract] [Full Text] [Related]
18. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
Yang H; Zhang Q; Xu M; Wang L; Chen X; Feng Y; Li Y; Zhang X; Cui W; Jia X
Mol Cancer; 2020 Feb; 19(1):41. PubMed ID: 32103760
[TBL] [Abstract] [Full Text] [Related]
19. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.
Sudo S; Kajiya H; Okano S; Sasaki M; Katsumata Y; Ohno J; Ikebe T; Hiraki A; Okabe K
Cancer Sci; 2020 Apr; 111(4):1113-1123. PubMed ID: 32012401
[TBL] [Abstract] [Full Text] [Related]
20. PROGRAMMED CELL DEATH-LIGand 1 OVEREXPRESSION IN THYROID cancer.
Zhang GQ; Wei WJ; Song HJ; Sun ZK; Shen CT; Zhang XY; Chen XY; Qiu ZL; Luo QY
Endocr Pract; 2019 Mar; 25(3):279-286. PubMed ID: 30913016
[TBL] [Abstract] [Full Text] [Related]
[Next]
